Learn More
Acute myeloid leukaemia is a highly malignant haematopoietic tumour that affects about 13,000 adults in the United States each year. The treatment of this disease has changed little in the past two decades, because most of the genetic events that initiate the disease remain undiscovered. Whole-genome sequencing is now possible at a reasonable cost and(More)
Most patients with acute myeloid leukaemia (AML) die from progressive disease after relapse, which is associated with clonal evolution at the cytogenetic level. To determine the mutational spectrum associated with relapse, we sequenced the primary tumour and relapse genomes from eight AML patients, and validated hundreds of somatic mutations using deep(More)
Most mutations in cancer genomes are thought to be acquired after the initiating event, which may cause genomic instability and drive clonal evolution. However, for acute myeloid leukemia (AML), normal karyotypes are common, and genomic instability is unusual. To better understand clonal evolution in AML, we sequenced the genomes of M3-AML samples with a(More)
Myelodysplastic syndromes (MDS) are hematopoietic stem cell disorders that often progress to chemotherapy-resistant secondary acute myeloid leukemia (sAML). We used whole-genome sequencing to perform an unbiased comprehensive screen to discover the somatic mutations in a sample from an individual with sAML and genotyped the loci containing these mutations(More)
Next-generation sequencing has been used to infer the clonality of heterogeneous tumor samples. These analyses yield specific predictions-the population frequency of individual clones, their genetic composition, and their evolutionary relationships-which we set out to test by sequencing individual cells from three subjects diagnosed with secondary acute(More)
Therapy-related acute myeloid leukaemia (t-AML) and therapy-related myelodysplastic syndrome (t-MDS) are well-recognized complications of cytotoxic chemotherapy and/or radiotherapy. There are several features that distinguish t-AML from de novo AML, including a higher incidence of TP53 mutations, abnormalities of chromosomes 5 or 7, complex cytogenetics and(More)
OBJECTIVE To describe epidemiologic features of pet evacuation failure after a hazardous chemical spill in which residents had no warning and only a few hours notice to evacuate. DESIGN Cross-sectional study. SAMPLE POPULATION Pet-owning households that evacuated from a hazardous chemical spill with (n = 119) or without (122) their pets.(More)
OBJECTIVE To determine risk factors for pet evacuation failure during a flood. DESIGN Cross-sectional survey. SAMPLE POPULATION 203 pet-owning households in a flooded region. PROCEDURES Persons under evacuation notice because of a flood were interviewed by use of a random telephone survey. RESULTS 102 households evacuated with their pets, whereas(More)
1. De novo AML in an adult patient less than 60 years old. Patients enrolled in the study were greater than 18 years of age, and with no antecedent history of myelodysplastic syndrome or prior chemotherapy or radiation therapy for cancer, since treatment‐related AML may have a different genetic basis than de novo AML. Further, several Cooperative Group(More)
# These authors contributed equally to this work. Therapy-related acute myeloid leukemia (t-AML) and therapy-related myelodysplastic syndrome (t-MDS) are well-recognized complications of cytotoxic chemotherapy and/or radiotherapy 1. There are several features that distinguish t-AML from de novo AML including a higher incidence of TP53 mutations 2,3 ,(More)